Free tool
Cell therapy stocks
We cover 8 companies grouped under the Cell therapy theme. The median market value in the group is $24.35M. Across the group, the median move over the past trading day is −2.14%. Price change over the past year runs from −60.8% to +13.2% across the middle 80 percent of the group, with a median of −45.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 86 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| V3V.DE | FamiCord AG | $58.21M | Micro cap | −60.69% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $53.78M | Micro cap | +81.25% |
| PTG.WA | Poltreg S.A. | $36.84M | Micro cap | −16.00% |
| PSH0.DE | Sernova Biotherapeutics Inc | $26.97M | Micro cap | −46.78% |
| 0NLV.L | FamiCord AG | $21.73M | Micro cap | −61.12% |
| F98.F | CytoMed Therapeutics Limited | $11.54M | Micro cap | −54.82% |
| 0QFK.L | Celyad Oncology SA | $4.54M | Micro cap | −16.07% |
| BSFA.L | BSF Enterprise Plc | $3.04M | Micro cap | −44.44% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.